{
    "clinical_study": {
        "@rank": "104003", 
        "acronym": "H11", 
        "arm_group": [
            {
                "arm_group_label": "experimental arm", 
                "arm_group_type": "Experimental", 
                "description": "An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.\nOnly patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
            }, 
            {
                "arm_group_label": "standard arm", 
                "arm_group_type": "Active Comparator", 
                "description": "A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.\nOnly patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of the trial is to show that doxorubicin, bleomycin, vinblastine, and\n      dacarbazine (ABVD)-based response-adapted therapy for advanced-stage Hodgkin lymphoma, with\n      treatment intensification (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine,\n      procarbazine, and prednisone (BEACOPPesc) in case of a positive fluorodeoxyglucose (FDG)\n      positron emission tomography (PET) computed tomography (CT) after one cycle of ABVD, has\n      non-inferior efficacy compared with the intensive BEACOPPesc regimen. A second objective is\n      to assess the prognostic value of FDG-PET/CT after one cycle of BEACOPPesc."
        }, 
        "brief_title": "Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)", 
        "completion_date": {
            "#text": "March 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Previously untreated, histologically proven classical Hodgkin lymphoma\n\n          -  Clinical stages III/IV (Ann Arbor)\n\n          -  Age 18-60\n\n          -  WHO performance 0-2\n\n          -  Adequate organ function\n\n          -  Patients of childbearing/reproductive potential should use adequate birth control\n             measures during the whole duration of study treatment.\n\n          -  Written informed consent according to ICH/EU Good Clinical Practice, and\n             national/local regulations\n\n        Exclusion criteria:\n\n          -  Pregnancy or lactation\n\n          -  Specific contraindications to BEACOPPesc therapy, including:\n\n          -  Poorly controlled diabetes mellitus\n\n          -  HIV infection,\n\n          -  Chronic active hepatitis B and/or hepatitis C\n\n          -  Concomitant or previous malignancies with the exception of basal cell skin tumors,\n             adequately treated carcinoma in situ of the cervix and any cancer that has been in\n             complete remission for >5 years\n\n          -  Psychological, familial, sociological or geographical condition potentially hampering\n             compliance with the study protocol and follow-up schedule; those conditions should be\n             discussed with the patient before registration in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "570", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652261", 
            "org_study_id": "EORTC-20101-23101", 
            "secondary_id": "2011-005473-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "experimental arm", 
                "intervention_name": "ABVD + FDG-PET/CT Scan treatment adaptation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "experimental arm", 
                    "standard arm"
                ], 
                "intervention_name": "BEACOPPesc", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "advanced stage", 
        "lastchanged_date": "June 18, 2013", 
        "location": {
            "contact": {
                "last_name": "Martin Hutchings, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "2100"
                }, 
                "name": "Rigshospitalet"
            }, 
            "investigator": {
                "last_name": "Martin Hutchings, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group", 
        "overall_contact": {
            "email": "alice.preumont@eortc.be", 
            "last_name": "Alice Preumont", 
            "phone": "+32 2 774 15 10"
        }, 
        "overall_official": [
            {
                "affiliation": "Rigshospitalet, Denmark", 
                "last_name": "Martin Hutchings", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "The Netherlands Cancer Institute, Amsterdam, The Netherlands", 
                "last_name": "Berthe Aleman", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University Medical Centre Groningen", 
                "last_name": "Gustaaf van IMHOFF", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Radboud University", 
                "last_name": "Wim Oyen", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Freedom from treatment failure", 
            "safety_issue": "No", 
            "time_frame": "9 years after first patient in (FPI)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652261"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "response at the end of therapy", 
                "safety_issue": "No", 
                "time_frame": "9 years after FPI"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "9 years after FPI"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "9 years after FPI"
            }, 
            {
                "description": "Hematological toxicity (blood cell count) can be significant especially for patients who will receive BEACOPPesc .\nBleomycine interstitial pneumonitis has been frequently reported and requires the immediate stop of further bleomycine administration.\nRarely, procarbazine allergy and intolerance has been reported.\nNausea & vomiting due to cyclophosphamide, doxorubicin, dacarbazine and procarbazine may be significant.\nTotal reversible alopecia occurs in most cases.\nEscalated BEACOPP-related toxic deaths have been reported but do not exceed those observed with standard ABVD.", 
                "measure": "Acute toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "9 years after FPI"
            }, 
            {
                "measure": "Long-term toxicity in terms of second malignancies, cardiovascular and pulmonary events", 
                "safety_issue": "Yes", 
                "time_frame": "9 years after FPI"
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "collaborator": {
                "agency": "Polish Lymphoma Research Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}